Advocacy intelligence hub — real-time data for patient organizations
Oslo University Hospital — PHASE2
The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Imatinib Mesylate
(IMATINIB)Orphan drugstandardMylan Institutional Inc
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Imkeldi
(IMATINIB ORAL)Orphan drugstandardShorla Oncology Inc.,
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Imatinib Mesylate
(IMATINIB MESYLATE)Orphan drugstandardApotex Corp
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Sandra D'Angelo, MD, PhD
Memorial Sloan Kettering Cancer Center
📍 SPRINGFIELD, MO
Selma Ugurel, MD
Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany
Kjetil Boye, MD, PhD
Oslo University Hospital
Ivar Hompland, MD, PhD
Oslo University Hospital
Candace L Haddox, M.D
Dana-Farber - Harvard Cancer Center LAO
📍 BOSTON, MA
Margaret von Mehren
Fox Chase Cancer Center